Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Addiction Medicine Psychiatrists (US)

Articles with lock require a subscription to GLG News | Request a free trial
October 12, 2007
Treating Obesity is not Like Taking out the Appendix
Analysis of: Weight Loss Maintenance for Kids Benefits from Extended Intervention | www.medpagetoday.com
Author: GLG Expert Contributor
Obesity treatment works in the short-term but likely needs to be extended over a life-time to be continuously effective.  This is the same as management of any chronic illness.  The surgical intervention model of a single procedure to "cure" complex biopsychosocial problems is naive and s...
October 11, 2007
Vanda"s Iloperidone: Lemonade or Lemon
Analysis of: Vanda Pharmaceuticals Submits Iloperidone New Drug Application | www.pipelinereview.com
Author: Lawrence Ginsberg, President, Red Oak Psychiatry Associates, P. A.
1. Iloperidone has demonstrated efficacy in treating positive and negative symptoms of schizophrenia and also has a favorable safety profile. 2. Vanda has utilized pharmacogenetic studies to identify a group of schizophrenic patients that will benefit from this agent that binds to a number of serotonin...
October 9, 2007
The Problem is Rarely the Drug Alone...
Analysis of: Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels | www.pipelinereview.com
Author: GLG Expert Contributor
I often marvel at the way different drugs weather the FDA storm and the varying vehemence of the press in terms of how they hold the respective pharmaceutical companies responsible for their products.  Chronic use of olanzapine causes significant metabolic changes which are likely to have adverse...
October 8, 2007
DOV 21,947: A Triple Reuptake Inhibitor With a Favorable Metabolic Profile
Analysis of: DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study | www.medicalnewstoday.com
Author: Lawrence Ginsberg, President, Red Oak Psychiatry Associates, P. A.
1. DOV 21,947 in a phase Ib study produced a statistically significant reduction in plasma triglyceride levels, body weight, and Body Mass Index (BMI). 2. This compound is believed to not only manage depression but also impact weight gain. 3. A phase II study of DOV 21,947 is being delayed until the...
October 1, 2007
Know Thy Patient before You Leap to Conclusions
Analysis of: FDA Warns About Misuse Of Fentora Cancer Pain Drug | www.medicalnewstoday.com
Author: GLG Expert Contributor
It is very important to understand that potent opioid agonists should only be used when a patient has had long-term opioid treatment.  Moreover, breakthrough pain has significant psychological overlay and using a cannon when a small pistol will do is potentially a reaction of the physician who...
September 27, 2007
You look Malvelous...who cares how you feel
Analysis of: Feel Pudgy? There’s a Shot for That | www.nytimes.com
Author: GLG Expert Contributor
Beware of easy solutions for feeling pudgy, they may decrease fat deposits but will they change your self-image?  To add to the problem, regulation in this field is miniscule.  Will we have a repeat of breast implants, namely adding fat "in all the right places"?
September 18, 2007
Shire Takes Proactive Stance Regarding Daytrana Skin Patches
Analysis of: Shire withdraws some ADHD skin patches | www.reuters.com
Author: Lawrence Ginsberg, President, Red Oak Psychiatry Associates, P. A.
1. Shire has withdrawn patches that had defective patch liners. 2. This defect is not related to safety or efficacy issues. 3. The cost to Shire is less than $10 million.
September 17, 2007
Adlea focuses on pain transmitting neurons rather than the brain and should be very helpful for those who should not use opiates
Analysis of: Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery | www.pipelinereview.com
Author: GLG Expert Contributor
While opioids are arguably the best analgesics for acute and subacute pain there are significant systemic side effects such as mental status changes and nausea which do not make it ideal.  There are those who are addiction-prone or have previously had addiction who should avoid opioids or other...
September 14, 2007
Patients should BLOOM on this regimen of combined behavioral and pharmacotherapy
Analysis of: Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review | www.medicalnewstoday.com
Author: GLG Expert Contributor
BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) is interesting in that it recognizes the need to test any pharmaceutical approaches to obesity within the background of behavioral interventions.  This is for a number of reasons, most important among these is...
September 12, 2007
New Potentially Effective Antidepressants to be Marketed by a Potentially Effective Alliance
Analysis of: Lundbeck and Takeda form Alliance to Develop and Commercialize a Portfolio of Novel Compounds in the US and Japan for the Treatment of Mood and Anxiety Disorders | www.pipelinereview.com
Author: Lawrence Ginsberg, President, Red Oak Psychiatry Associates, P. A.
1. Lu AA21004 and Lu AA24530 are two compounds with a great deal of potential and will be co-marketed jointly by Takeda and Lundbeck. 2. Lu AA21004 is the more advanced of the compounds and is currently in phase II development for the treatment of major depression. 3. The compounds potentially address...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 132

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-11-21T05:45:43.110